ACR 2316
Alternative Names: ACR-2316Latest Information Update: 05 Nov 2024
Price :
$50 *
At a glance
- Originator Acrivon Therapeutics
- Class Antineoplastics
- Mechanism of Action PKMYT1 protein inhibitors; WEE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Cancer
Most Recent Events
- 08 Oct 2024 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease, Recurrent) in USA (unspecified route) (NCT06667141)
- 05 Apr 2024 Pharmacodynamics data from preclinical trial in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Acrivon Therapeutics plans clinical monotherapy development